Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2007

01-02-2007

Asymptomatic Colorectal Cancer with Un-Resectable Liver Metastases: Immediate Colorectal Resection or Up-Front Systemic Chemotherapy?

Authors: Andrea Muratore, MD, Daria Zorzi, MD, Hedayat Bouzari, MD, Marco Amisano, MD, Paolo Massucco, MD, Elisa Sperti, MD, Lorenzo Capussotti, MD

Published in: Annals of Surgical Oncology | Issue 2/2007

Login to get access

Abstract

Background

About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases. Resection of colorectal cancer in patients with moderate-severe symptoms is mandatory before starting chemotherapy. Surgical treatment of asymptomatic colorectal cancers is still a matter of discussion.

Methods

From January 2000 to December 2004, we prospectively collected data on 35 consecutive patients who were treated straightaway by chemotherapy without primary tumor resection. All patients underwent FOLFOX6 as first-line chemotherapy. The aim of the study was to evaluate the rate of surgical complications related to un-resected colorectal tumor.

Results

The mean interval between diagnosis and start of chemotherapy was 23.1 days (95% CI: 17.3–28.8). Fifteen of the 35 patients (42.9%) were down-staged to surgery; the mean interval between chemotherapy start and colon-rectum cancer resection was 6.5 months (95% CI: 5.5–7.5). None of them developed complications related to the primary tumor during chemotherapy. Of the other 20 patients who did not undergo any curative surgery, 16 received a second line chemotherapy and 10 a third line: six patients are alive and without intestinal symptoms (mean follow up 22.5 months, 95% CI: 11.2–33.9). Only one patient (2.8%) developed clinical signs of intestinal occlusion 5.6 months from the start of chemotherapy and required urgent colostomy.

Conclusions

The rate of complications related to the non-resected colorectal tumor is very low using oxaliplatin as first line chemotherapy. Non-operative management of asymptomatic colorectal cancers with un-resectable liver metastases is a safe approach.
Literature
1.
go back to reference Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321:531–5CrossRef Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321:531–5CrossRef
2.
go back to reference Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663–669PubMedCrossRef Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663–669PubMedCrossRef
3.
go back to reference Joffe J, Gordon PH. Palliative resection for colorectal carcinoma. Dis Colon rectum 1981; 24:355–360PubMedCrossRef Joffe J, Gordon PH. Palliative resection for colorectal carcinoma. Dis Colon rectum 1981; 24:355–360PubMedCrossRef
4.
go back to reference Longo WE, Ballantyne GH, Bilchik AJ, Modlin IM. Advanced rectal cancer. What is the best palliation ? Dis Colon Rectum 1988; 31:842–847PubMedCrossRef Longo WE, Ballantyne GH, Bilchik AJ, Modlin IM. Advanced rectal cancer. What is the best palliation ? Dis Colon Rectum 1988; 31:842–847PubMedCrossRef
5.
go back to reference Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, Millis M, Posner MC. Initial presentation with stage IV colorectal cancer. How aggressive should we be? Arch Surg 2000; 135:530–535PubMedCrossRef Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, Millis M, Posner MC. Initial presentation with stage IV colorectal cancer. How aggressive should we be? Arch Surg 2000; 135:530–535PubMedCrossRef
6.
go back to reference Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196:722–728. DOI: 10.1016/S1072-7515(03)00136-4PubMedCrossRef Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003; 196:722–728. DOI: 10.1016/S1072-7515(03)00136-4PubMedCrossRef
7.
go back to reference Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6:651–657PubMedCrossRef Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6:651–657PubMedCrossRef
8.
go back to reference Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 2005; 92:1155–1160. DOI: 10.1002/bjs.5060PubMedCrossRef Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 2005; 92:1155–1160. DOI: 10.1002/bjs.5060PubMedCrossRef
9.
go back to reference Sarela AI, Guthrie JA, Seymourt MT, Ride E, Guillou PJ, O’Riordain S. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001; 88:1352–1356PubMedCrossRef Sarela AI, Guthrie JA, Seymourt MT, Ride E, Guillou PJ, O’Riordain S. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 2001; 88:1352–1356PubMedCrossRef
10.
go back to reference Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205–216PubMedCrossRef
11.
go back to reference Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986; 57:1866–1870PubMedCrossRef Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986; 57:1866–1870PubMedCrossRef
12.
go back to reference Finan PJ, Marshall RJ, Cooper EH, Giles GR. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985; 72:373–7PubMedCrossRef Finan PJ, Marshall RJ, Cooper EH, Giles GR. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985; 72:373–7PubMedCrossRef
13.
go back to reference Goslin R, Steele G Jr, Zamcheck N, Mayer R, MacIntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982; 25:749–54PubMedCrossRef Goslin R, Steele G Jr, Zamcheck N, Mayer R, MacIntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982; 25:749–54PubMedCrossRef
14.
go back to reference Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141:586–9PubMedCrossRef Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141:586–9PubMedCrossRef
15.
go back to reference Moran MR, Rothenberger DA, Lahr CJ, Buls JG, Goldberg SM. Palliation for rectal cancer. Resection? Anastomosis? Arch Surg 1987; 122:640–643PubMed Moran MR, Rothenberger DA, Lahr CJ, Buls JG, Goldberg SM. Palliation for rectal cancer. Resection? Anastomosis? Arch Surg 1987; 122:640–643PubMed
16.
go back to reference Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Teniere P, Paillot B. Colorectal cancer with non-resectable synchronous metastases: should the primari tumor be resected? Gastroenterol Clin Biol 2004; 28:434–437PubMedCrossRef Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Teniere P, Paillot B. Colorectal cancer with non-resectable synchronous metastases: should the primari tumor be resected? Gastroenterol Clin Biol 2004; 28:434–437PubMedCrossRef
17.
go back to reference Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005; 89:211–217PubMedCrossRef Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005; 89:211–217PubMedCrossRef
18.
go back to reference Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingstone S, Andreyev J. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52:568–573PubMedCrossRef Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingstone S, Andreyev J. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52:568–573PubMedCrossRef
19.
go back to reference de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freqyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–2947PubMed de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freqyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–2947PubMed
20.
go back to reference Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243–9249. DOI: 10.1200/JCO.2005.07.740PubMedCrossRef Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243–9249. DOI: 10.1200/JCO.2005.07.740PubMedCrossRef
21.
go back to reference Tournigand C, Andrè T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, landi B, Colin P,Louvet C, de Gramont A. FOLFIRI follone by FOLFOX6 or the riverse sequenze in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–237. DOI: 10.1200/JCO.2004.05.113PubMedCrossRef Tournigand C, Andrè T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, landi B, Colin P,Louvet C, de Gramont A. FOLFIRI follone by FOLFOX6 or the riverse sequenze in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–237. DOI: 10.1200/JCO.2004.05.113PubMedCrossRef
22.
go back to reference Cohen AM. What is the best treatment for stage IV colorectal cancer? Ann Surg Oncol 2005; 12:581–582. DOI: 10.1245/ASO.2005.03.901PubMedCrossRef Cohen AM. What is the best treatment for stage IV colorectal cancer? Ann Surg Oncol 2005; 12:581–582. DOI: 10.1245/ASO.2005.03.901PubMedCrossRef
23.
go back to reference Wichmann MW, Huttl TP, Winter H, Spelsberg F, Angele MK, Heiss MM, Jauch KW. Immunological effects of laparoscopic vs open colorectal surgery. Arch Surg 2005; 140:692–697PubMedCrossRef Wichmann MW, Huttl TP, Winter H, Spelsberg F, Angele MK, Heiss MM, Jauch KW. Immunological effects of laparoscopic vs open colorectal surgery. Arch Surg 2005; 140:692–697PubMedCrossRef
24.
go back to reference Jarnagin WR, Delman K, Kooby D, Mastorides S, Zager J, Brennan MF, Blumgart LH, Federoff H, Fong Y. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg 2000; 231:762–71PubMedCrossRef Jarnagin WR, Delman K, Kooby D, Mastorides S, Zager J, Brennan MF, Blumgart LH, Federoff H, Fong Y. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg 2000; 231:762–71PubMedCrossRef
Metadata
Title
Asymptomatic Colorectal Cancer with Un-Resectable Liver Metastases: Immediate Colorectal Resection or Up-Front Systemic Chemotherapy?
Authors
Andrea Muratore, MD
Daria Zorzi, MD
Hedayat Bouzari, MD
Marco Amisano, MD
Paolo Massucco, MD
Elisa Sperti, MD
Lorenzo Capussotti, MD
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9146-1

Other articles of this Issue 2/2007

Annals of Surgical Oncology 2/2007 Go to the issue

Resident/Fellow Essay Award Winner for the Best Clinical Research Paper Basic Science and Special Investigator Award Winners

Lymphatic Drainage of the Peritoneal Space: A Pattern Dependent on Bowel Lymphatics